Known Interactions Between Ezetimibe and Vascepa
No major pharmacokinetic interactions occur between ezetimibe (a cholesterol absorption inhibitor) and Vascepa (icosapent ethyl, a purified EPA omega-3). They target different lipid pathways—ezetimibe blocks intestinal cholesterol uptake, while Vascepa reduces triglycerides via PPAR activation—and studies show no significant changes in plasma levels or efficacy when combined.[1][2]
Common Side Effects of Each Drug
- Ezetimibe alone: Muscle pain (myalgia, 3-5% of patients), diarrhea (4%), upper respiratory infections (4%), and rare liver enzyme elevations.[3]
- Vascepa alone: Arthralgia (3%), gout flares (1-3%), atrial fibrillation (5% in high-risk patients from REDUCE-IT trial), and bleeding risk (e.g., epistaxis, 2-3%).[4][5]
Combination does not amplify these uniquely, per available data.
Potential Risks When Combined
- Bleeding concerns: Vascepa slightly increases bleeding risk, especially with antiplatelets/anticoagulants; ezetimibe has no such effect, but monitor in patients on dual therapy.[5]
- Muscle-related issues: Both can cause myopathy rarely; no additive risk documented, but statins (often paired with ezetimibe) heighten this—report unexplained weakness.[3][6]
- Gout flares: Vascepa may raise uric acid; ezetimibe neutral, so no interaction noted.[4]
Clinical trials and post-marketing data (e.g., EVAPORATE, ongoing combo studies) report no unexpected adverse events beyond individual profiles.[2][7]
Patient Monitoring and Precautions
Check liver function, lipids, and bleeding parameters periodically. Avoid in active liver disease or hypersensitivity. REDUCE-IT subgroup analyses support combo safety in cardiovascular patients, but consult providers for personalized risks like CKD or diabetes.[5][8]
Alternatives if Concerns Arise
Switch to rosuvastatin/ezetimibe fixed-dose (Roszet) plus lifestyle, or bempedoic acid for statin-intolerant cases. Omega-3 alternatives like Lovaza carry similar bleeding risks.[9]
[1]: FDA Label - Vascepa
[2]: DrugPatentWatch.com - Ezetimibe Patents (interaction data via API)
[3]: FDA Label - Ezetimibe
[4]: REDUCE-IT Trial, NEJM 2019
[5]: Vascepa Prescribing Info Update 2020
[6]: Ezetimibe-Simvastatin Label
[7]: EVAPORATE Trial, JACC 2020
[8]: AHA Guidelines on Lipids 2018
[9]: Drugs.com Interaction Checker